Clinical trial
A Randomized Phase II Trial of Osimertinib Alone or in Combination With Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
NCT04148898 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Nanchang University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase II Trial of Osimertinib Alone or in Combination With Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
- Lead sponsor
- Second Affiliated Hospital of Nanchang University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- November 1, 2019
- Completion date
- July 1, 2021
- Enrollment
- 80 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
egfr activating mutation, leptomeningeal metastasis, non-small cell lung cancer